CoreCivic Reports First Quarter 2026 Financial Results
CoreCivic reported strong Q1 2026 results, with revenue rising 25.8% year-over-year to $614.7 million and Adjusted EBITDA increasing 36% to $110.1 million, driven by the activation of four previously idled facilities. The company raised its full-year 2026 guidance for Adjusted Diluted EPS to $1.53-$1.63 and Adjusted EBITDA to $453.8M-$461.8M, reflecting the recent $148 million acquisition of Clinical Solutions Pharmacy.
Key figures
- Eps
- 0.38
- Revenue
- $614.7 million
- Guidance
- Full Year 2026 Adjusted Diluted EPS raised to $1.53-$1.63 (from $1.49-$1.59); Adjusted EBITDA raised to $453.8M-$461.8M (from $437.0M-$445.0M).
- Revenue Yoy
- 25.8%
- Net income
- $37.9 million
- Adjusted eps
- 0.4
- Deal Value Usd
- 148000000
- Adjusted ebitda
- $110.1 million
- Repurchase cost
- $44.7 million
- Shares repurchased
- 2300000
- Normalized ffo per share
- 0.65
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.